DGAP-News: MPH Mittelständische Pharma Holding AG

DGAP-News: MPH Mittelständische Pharma Holding AG: Preliminary IFRS results for first half-year 2016:

DGAP-News: MPH Mittelständische Pharma Holding AG / Key word(s): Half Year Results/Dividend MPH Mittelständische Pharma Holding AG: Preliminary IFRS results for first half-year 2016:

30.08.2016 / 09:38 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

MPH Mittelständische Pharma Holding AG:

Preliminary IFRS results for first half-year 2016:

Net profit EUR 19.88 million (46 Cent per share) in first half-year, profit increase in second quarter of 29% compared to first quarter 2016, equity EUR 153.49 million (3.58 EUR per share)

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), reports its preliminary IFRS Group results for the first half-year 2016.

In the first half-year 2016 the preliminary IFRS Group net profit amounted to EUR 19.88 million.

The investments listed on Frankfurt Stock Exchange, HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG performed successfully in the first half- year 2016.

HAEMATO achieved in the first half-year sales growth and profit (EBIT) growth of 40%. M1 Kliniken AG enlarged the clinic in Berlin to six operating rooms and 34 patient beds. After further openings M1 is now active with twelve M1-outpatient service centres throughout Germany. Sales of EUR 18.5 million in the first half-year shall be outperformed in the second half-year. Both companies, HAEMATO and M1, paid a dividend of 30 Cent per share to their shareholders in June 2016.

CR Capital Real Estate AG reported on its general annual meeting on August 18th about progress in the project developments.

MPH paid a dividend of 12 Cent per share in June 2016.

"The net income of EUR 11.19 million in the first quarter outperformed the net income of EUR 8.69 million achieved in the first quarter by 28.7%

We saw in the second quarter a successful development in the effort to make a contribution in keeping healthcare affordable and we are confident for the further income development in 2016", say Patrick Brenske und Dr. Christian Pahl, Members of the Management Board of MPH.

About MPH Mittelständische Pharma Holding AG:

MPH AG is an investment entity strategically focused on the purchase, development and sale of companies and shares in companies especially from the growth segments of the healthcare market. This includes insurance reimbursed segments as well as privately financed segments. But also beyond the healthcare market MPH makes use of potentials of high growth areas.

Key figures for the share of MPH Mittelständische Pharma Holding AG: Subscribed capital: EUR 42,813,842 Listed shares: ordinary shares ISIN: DE000A0L1H32 WKN: A0L1H3 Stock symbol: 93M

Contact: Susanne Seger MPH Mittelständische Pharma Holding AG Grünauer Straße 5 D-12557 Berlin

Phone: +49 (0) 30 897308660 Fax: +49 (0) 30 897308669 E-Mail: ir@mph-ag.de Web: www.mph-ag.de

---------------------------------------------------------------------------

30.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English Company: MPH Mittelständische Pharma Holding AG Grünauer Straße 5 12557 Berlin Germany Phone: 030 / 897 308 660 Fax: 030 / 897 308 669 E-mail: info@mph-ag.de Internet: www.mph-ag.de ISIN: DE000A0L1H32 WKN: A0L1H3 Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart, Tradegate Exchange; Open Market (Entry Standard) in Frankfurt End of News DGAP News Service ---------------------------------------------------------------------------

496953 30.08.2016